User:Mr. Ibrahem/Tolcapone

Mr. Ibrahem/Tolcapone
Clinical data
Trade names	Tasmar
AHFS/Drugs.com	Monograph
MedlinePlus	a698036
License data	EU EMA: by INN; US DailyMed: Tolcapone;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
Drug class	COMT inhibitor
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	65%
Protein binding	>99.9%
Metabolism	Liver (mainly glucuronidation)
Elimination half-life	2–3 hours
Excretion	Urine (60%), feces (40%);; only 0.5% in unmetabolized form
Identifiers
	IUPAC name (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone;
Chemical and physical data
Formula	C14H11NO5
Molar mass	273.244 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	143 to 146 °C (289 to 295 °F)
Solubility in water	not soluble
	SMILES [O-][N+](=O)c2cc(C(=O)c1ccc(cc1)C)cc(O)c2O;
	InChI InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3 ; Key:MIQPIUSUKVNLNT-UHFFFAOYSA-N ;
	(verify)

Tolcapone, sold under the brand name Tasmar, is a medication used to treat Parkinson's disease (PD).^[2] It is taken together with levodopa/carbidopa.^[2] It is taken by mouth.^[2] If people do not see improvement within 3 weeks it should be stopped.^[2]

Common side effects include nausea, loss of appetite, movement disorders, headache, increased dreams, and confusion.^[3] Other side effects may include liver problems, which can be severe, and psychosis.^[2] It is an inhibitor of catechol-O-methyltransferase (COMT).^[1]

Tolcapone was approved for medical use in Europe in 1997 and the United States in 1998.^[3]^[2] It is available as a generic medication.^[4] In the United Kingdom 100 tablets of 100 mg costs the NHS about £95 in 2021.^[5] This amount in the United States costs about 1,200 USD.^[4] It is not commonly used due to side effects.^[1]

References edit

^ ^a ^b ^c Antonini A, Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Onofrj M, et al. (February 2008). "COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features". Neuropsychiatric Disease and Treatment. 4 (1): 1–9. doi:10.2147/NDT.S2404. PMC 2515921. PMID 18728767.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ ^a ^b ^c ^d ^e ^f ^g ^h "Tolcapone Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 5 October 2021.
^ ^a ^b ^c "Tasmar". Archived from the original on 10 January 2021. Retrieved 6 October 2021.
^ ^a ^b "Tolcapone Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 6 October 2021.
^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 433. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[Ant2008-1] Antonini A, Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Onofrj M, et al. (February 2008). "COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features". Neuropsychiatric Disease and Treatment. 4 (1): 1–9. doi:10.2147/NDT.S2404. PMC 2515921. PMID 18728767.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Tolcapone Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 5 October 2021.

[EPAR2021-3] "Tasmar". Archived from the original on 10 January 2021. Retrieved 6 October 2021.

[GX2021-4] "Tolcapone Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 6 October 2021.

[BNF80-5] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 433. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[1]

[2]

[3]

[4]

[5]